Arca
Skip to content
Tools
Tools

PLAU: Urokinase-type plasminogen activator

Serine protease that cleaves the inactive precursor plasminogen at a specific Arg-Val peptide bond, converting it into active plasmin.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on PLAU, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved1

  • Urokinase

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        UrokinaseApprovedMicrobix BiosystemsProtein or peptideExogenous proteinUrokinase-type plasminogen activator exogenous protein20

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 HoursUrokinasePhase 3Not yet recruitingThe First Affiliated Hospital of University of Science and Technology of ChinaNov 12, 2026
        Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid TumorsUrokinaseEarly phase 1Not yet recruitingHua PangJun 10, 2026
        Early Lumbar Drainage for Intraventricular HemorrhageUrokinaseNot applicableNot yet recruitingSecond Affiliated Hospital of Nanchang UniversityJun 4, 2026
        Pro-urokinase for Extended-Window Posterior Circulation StrokeUrokinasePhase 3Not yet recruitingThe First Affiliated Hospital of Zhengzhou UniversityJun 1, 2026
        STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary EmbolismUrokinase—Not yet recruitingNanjing First Hospital, Nanjing Medical UniversityMay 22, 2026
        Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial)UrokinaseNot applicableNot yet recruitingUniversità Politecnica delle MarcheApr 24, 2026
        TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral HemorrhageUrokinaseNot applicableRecruitingXuanwu Hospital, BeijingSep 23, 2025
        Timing and Outcomes of Recovery After intraCerebral HemorrhageUrokinase—RecruitingXuanwu Hospital, BeijingSep 10, 2025

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Quebec platelet disorder
        0.62
        Abdominal aortic aneurysm
        0.52
        Recurrent thrombophlebitis
        0.37
        Psoriasis vulgaris
        0.34
        Empyema
        0.27
        Stroke disorder
        0.27

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3286, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00749, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.